Together, IV therapies of various nutrients are amazing alternatives to medications and other invasive therapies
Diabetic dermopathy, necrobiosis lipoidica, or infections may occur independently of semaglutide use but require appropriate management
While take-up is uncertain, interest in the program among potentially eligible Medicare beneficiaries is likely to be strong
INFOGRAPHIC: Inside the GLP-1 Boom: Trends in Off-Label Use from Inovalons Primary Source Data GLP-1 agonists, like semaglutide (Ozempic), are changing the face of diabetes care while also gaining traction for off-label use
Timing, dosing, and routine all play a role in how effectively the body responds
Not always 15-20% like the high-dose clinical trials, but 5-10% is common